Pulse Biosciences, Inc Common Stock (DE) (PLSE) Stock
Fundamentals
Recent news

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
PLSE

Why Pulse Biosciences Stock Popped Today
Why Pulse Biosciences Stock Popped Today
PLSE

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PLSE

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PLSE
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
PLSE

Why Pulse Biosciences Stock Popped Today
Why Pulse Biosciences Stock Popped Today
PLSE

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PLSE

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PLSE

Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
PLSE

Pulse Biosciences Q2 Earnings Call Highlights
Pulse Biosciences Q2 Earnings Call Highlights
PLSE

Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimates
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimates
PLSE

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
PLSE

Pulse Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
Pulse Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
PLSE

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
PLSE
About Pulse Biosciences, Inc Common Stock (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Paul Arthur LaViolette M.B.A. | President, CEO & Co-Chairman of the Board | 1958 |
| Mr. Jon Skinner | Chief Financial Officer | 1986 |
| Mr. Darrin R. Uecker | CTO & Director | 1966 |
| Ms. Liane Teplitsky | Chief Operating Officer | 1977 |
| Mr. Steven T. Weber | VP of Accounting, Principal Accounting Officer & Global Corporate Controller | 1976 |
| Mr. Kenneth B. Stratton Esq., J.D. | General Counsel & Corporate Secretary | 1969 |
| Ms. Patty Perla | Vice President of Human Resources | — |
| Mr. David Danitz | Senior Vice President of Engineering | — |
| Dr. Gansevoort Dunnington M.D. | Chief Medical Officer | — |
| Dr. Niv Ad M.D. | Chief Science Officer of Cardiac Surgery | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
4 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -20.9 | +14.5 | -8.1 | +20.0 | +12.4 | +24.0 | +33.4 | -0.9 |



